红花注射液综合治疗对慢性肺心病急性期血液流变学的影响

目的：研究红花注射液对慢性肺心病急性期患者血液流变学及纤溶系统功能的影响。方法：选用60例慢性肺心病急性期患者，以随机双盲法平均分为两组，每组各30例。两组均予以抗炎，止咳化痰，强心利尿及持续低流量吸氧等常规治疗。红花组在常规治疗的基础上加用红花注射液静脉滴注，10天为1个疗程，间隔5天再进行第2个疗程，共治疗25天。对照组除不用红花注射液以外其余治疗及疗程与红花组相同。观察两组临床疗效，对血液流变性的影响及抗纤溶功能的作用。结果：临床总有效率红花组为86．7％，对照组为63．3％，两组比较有显著性差异（P＜0．05）。红花组治疗后高切变率下全血粘度、低切变率下全血粘度、血浆粘度、红细胞聚集指数、红细胞比积、纤维蛋白原与治疗前比较均显著下降（P＜0．01，P＜0．05），其血液流变性改善程度明显优于对照组。红花组血中抗凝血酶Ⅲ活性、纤溶酶原活性及组织型纤溶酶原激活物活性均较对照组明显升高（P＜0．05，P＜0．01），改善肺心病患者的抗凝及纤溶功能明显优于对照组。结论：红花注射液是一种治疗慢性肺心病急性期血液高凝状况的有效药物，值得临床推广运用。

英文摘要:

Objective: To study the effect of safflower injection (SI) on hemorrheology and fibrinolytic system in treat ing patients of chronic cor pulmonale during acute attack. Methods: Sixty patients were divided into two groups, 30 in each group. Both groups were treated with conventional therapy including anti-inflammatory, re lieving cough and reducing sputum, cardial, diuretic and continous low-flow oxygen inhalation. For the SI group, additional two courses of SI injection was given intravenously for 10 days as one course with an interval of 5 days between courses. The clinical therapeutic effect in the two groups and effect of treatment on hemorrheolo gy and fibrinolytic function were observed. Results: The total effective rate in the SI group was 86. 7% and that in the control group was 63. 3%, the difference between the two groups was significant (P<0.05). After treatment, in the SI group, the high- and low-shear whole blood viscosity, plasma viscosity, erythrocyte agglu tination index, hematocrit and fibrinogen lowered obviously, as compared with be fore treatment (P<0. 01 or P <0.05), and the improvement in hemorrheologic property was better than that in the control group significant ly(P<0.05). The blood activities of anti-thrombin Ⅲ, plasminogen and tectotype profibrinolytic activating factor were all higher than those in the control group (P<0.05, P<0.01). And SI showed more potent effect in improving anti-coagulation and fibrinolytic function of patients than that of the control (P<0. 05). Conclu sion: SI is an effective drug for treatment of hypercoagulability status in acute stage of chronic cor pulmonale,and is worthy of clinical application.

关闭